

Professional Provider Report

A newsletter for professional providers and their staff members
December 2024 - S-2-24

What's Inside

MagellanRX now Prime Therapeutics Specialty Pharmacy	1
Lucet resources for PCPs	2
Update reminder: CPT code 99459	2
Addition of Feraheme to IV Iron Preferred Products	3
Spevigo billing clarifications	3
New Ocular Angiogenesis Inhibitors medical policy	3
Medical assistance with smoking cessation	4

MagellanRX now Prime Therapeutics Specialty Pharmacy

Blue Cross and Blue Shield of Kansas (BCBSKS) is committed to bringing our members quality care at affordable prices. We partnered with CivicaScript to provide low cost abiraterone to our members, which required members to fill their abiraterone 250 milligram (mg) prescriptions at MagellanRx Specialty Pharmacy.

This past week, the specialty pharmacy underwent a rebranding process and updated their name to Prime Therapeutics Specialty Pharmacy. We wanted to notify you directly because you have written an abiraterone 250 mg prescription for one of our members that was filled at MagellanRx Specialty Pharmacy, now Prime Therapeutics Specialty Pharmacy. No new prescription is needed at this time.

The phone number (866-554-2673) and fax number (800-424-7913) are remaining the same, as is the location of the pharmacy. If you are prescribing abiraterone 250 mg again in the future, please note the name change to Prime Therapeutics Specialty Pharmacy. This information can be found on our website at bcbsks.com under the Prescription Drug tab by clicking on Specialty Pharmacy.

The Professional Provider Report is published by the Provider Relations department of Blue Cross and Blue Shield of Kansas.

Sarah Shaw,
Communications Coordinator



bcbsks.com

Lucet resources for PCPs

As a Primary Care Provider (PCP), you're often the first point of contact for patients experiencing behavioral health concerns. It's essential to recognize the signs of mental health issues, as untreated conditions can worsen, interfere with medical treatments, and lead to increased healthcare utilization.

One key resource available to you and your office staff, is Lucet's 24/7 PCP Physician Help Line at 877-280-9246. This line is available 24/7 and is dedicated to support physicians, nurses and other medical staff 24/7. The Lucet behavioral health professionals offer:

- Scheduling a consult with a Lucet psychiatrist on issues such as medication management
- Referrals for behavioral health services
- Telephonic services for high-risk patients
- Referrals to behavioral health case management
- Guidance for appropriate use of psychotropic medications
- Management of treatment access and follow-up for members with coexisting medical and behavioral disorders
- Consultation on special needs of members with severe and persistent mental illness

To support you in providing comprehensive care, the following resources are available:

- **Screening Tools:** Utilize validated screening instruments to identify mental health issues early.
- **Care Management Services:** Access care coordination to ensure holistic treatment.
- **Mental Health Awareness Toolkits:** Resources for managing common conditions like depression, anxiety, PTSD, and substance use disorders.
- **Behavioral Health Integration:** Integrate mental health care within your primary care practice.

These resources help address behavioral health concerns efficiently, ensuring better outcomes for your patients and improving their overall well-being.

Update reminder: CPT code 99459

Blue Cross and Blue Shield of Kansas (BCBSKS) would like to remind providers that CPT code 99459 captures the four minutes of clinical staff time associated with chaperoning a pelvic exam. Previously it was discovered the code was being reimbursed incorrectly. Claims with a service date of Oct. 1, 2024 or after will correctly deny content of service to the examination.

Please contact your professional provider representative if you have questions.



Addition of Feraheme to IV Iron Preferred Products

Blue Cross and Blue Shield of Kansas (BCBSKS) is constantly looking for ways to improve member and provider experience. We've identified an opportunity to do just that, by adding Feraheme as a preferred IV Iron product effective Oct. 1, 2024. This means that providers no longer need to submit a prior authorization (PA) for this medication, along with our other preferred IV Iron products, Ferrlecit, Infed, and Venofer.

The two novel agents, Monoferric and Injectafer, will still require a PA. Effective Oct. 1, 2024, providers should submit prior authorization forms to Prime Therapeutics for these two agents.

Spevigo billing clarifications

Spevigo is an interleukin-36 receptor antagonist approved for generalized pustular psoriasis (GPP). This product can be given intravenously (IV) for treatment of active flares and subcutaneously (SQ) as maintenance therapy for prevention of GPP when not experiencing flares. The Spevigo IV and SQ forms share a J-code. When submitting claims for Spevigo billing please include the NDC along with the J-code. This extra information aims to reduce processing time and improve accuracy in billing.



New Ocular Angiogenesis Inhibitors medical policy

The costs of medications are rising, and new, costly, intravitreal products have come to the market in recent years. At Blue Cross and Blue Shield of Kansas (BCBSKS), we consistently review our coverage stances and medical policies for medications to ensure that members have access to affordable treatment solutions that result in quality health outcomes. A recent review of common eye disease demonstrated a need for management of intravitreal medications as a result of increased utilization of the highest cost products in this treatment category.

What This Means

Effective Feb. 1, 2025, we will be implementing the Ocular Angiogenesis Inhibitors medical policy, which can be found on MyPrime.com, and requires the following:

- 1 Byooviz, Cimerli, and Lucentis will require a step through (1) intravitreal bevacizumab
- 2 Beovu, Eylea, Eylea HD, Pavblu and Vabysmo will require a step through (1) intravitreal bevacizumab and (2) one of Byooviz, Cimerli, or Lucentis

As of Feb. 1, 2025, a Prior Authorization (PA) will be required for all members for the targeted products, Cimerli, Lucentis, Byooviz, Beovu, Eylea, Eylea HD, Pavblu, and Vabysmo. When you submit for a PA, please submit all necessary information including chart notes, imaging, and medication trials.

Please note, a PA will not be required for bevacizumab when used for eye indications.

Next Steps

When you send authorization requests for targeted products above, please send them to Prime Therapeutics.

BCBSKS is here to help you and our members. If you have any questions, your provider representative would be happy to help.

Medical assistance with smoking cessation

Did you know that your patients covered by the Affordable Care Act or Marketplace insurance receive a survey about their care? One of the survey sections refers to the assistance you give to the patient (18 years or older) in ceasing smoking. Some of the things to know about this survey is that the questions may only refer to the last 6 months. To help your patients in remembering that you can assist them to quit when they are ready, consider the following:

- Ask them if they are smoking the same, less or not at all from your previous visits.
- Ask them if they are ready to stop smoking and feel they need assistance with medications.
- Offer them education/resource (i.e. American Lung Association) in writing with visit papers. Some patients may want to try counseling before medication.
- Offer them a resource to find out about the medications before a discussion if they are not sure they want to try a cessation medication. Seeing and hearing the medication name prior to the discussion may be less intimidating.

If you have any questions regarding this publication, please contact your BCBSKS provider representative.